Protive Bio

Protiva Biotherapeutics, Inc. is a development-stage biotechnology company primarily focused on developing nucleic acid-based pharmaceutical products. The company is dedicated to developing products to combat various human diseases such as cancer, influenza, Ebola virus, inflammatory diseases, and chronic viral infections. Its product portfolio includes Pro 1, a tumor cell growth inhibitor that can kill tumor cells and inhibit tumor growth; Pro-101, an siRNA product designed to suppress the production of proteins involved in tumor growth; Pro-B, which inhibits the expression of apolipoprotein B; Ebov-Protect and Marv-Protect, which can inhibit the replication of the Ebola and Marburg viruses; and Stable Nucleic Acid Lipid Particle (SNALP) technology, a delivery system for encapsulating nucleic acid payloads (such as short interfering RNA (siRNA)) to target cells.